Addex

Allosteric modulators for human health

  • About us
    • Addex Corporate Presentation
    • Overview
    • Our people
      • Executive Officers
      • Non-Executive Directors
      • Scientific Advisory Board
    • Contact
    • Privacy Policy
    • Careers
  • Pipeline
    • Clinical and Pre-Clinical Pipeline
    • Research And Development
  • Technology platform
    • Allosteric modulation
    • Our capabilities
      • Screening Assays
      • Chemistry
    • Publications
  • Partners & collaboration
  • Investors
    • Addex Corporate Presentation
    • Stock Data
    • Press releases
    • Ad hoc announcements (Art. 53 L.R)
    • Events
    • Financial Reports
    • Analyst Reports
    • General Meetings
    • SEC / SIX Filings
    • Guide to US ADSS for Six Shareholders
    • Register for email news
    • Corporate Governance
    • Contact
  • Media
    • Press releases
    • Contact
about us

about us

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Pipeline

Clinical and Pre-Clinical Pipeline

 

 

 

Research And Development

   

 

Publications
  • GABAB PAM for cough
  • M4 PAM for schizophrenia & other psychosis
  • ADX71149 for epilepsy
  • GABAB PAM for substance use disorder
  • Dipraglurant for post-stroke sensorimotor recovery
  • mGlu7 NAM for stress related disorders including PTSD
  • mGlu2 NAM for mild neurocognitive disorders
Placeholder image

Technology platform

Allosteric Modulation

Read more
Placeholder image

Partners & Collaborations

Industry

Read more

Latest news Latest news icon

  • 03.13
    2020

    Addex Therapeutics to Report 2019 Full Year Audited Results on March 19, 2020

  • 03.03
    2020

    Addex Therapeutics Appoints Prominent Neuroscience Drug Developer Darryle D. Schoepp PhD as Chairman of its Scientific Advisory Board

  • 02.26
    2020

    Addex Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference

  • 02.03
    2020

    Addex Therapeutics to Ring the Nasdaq Stock Market Closing Bell

  • 01.29
    2020

    Addex Starts Trading American Depositary Shares on Nasdaq Under Ticker ADXN

  • 01.13
    2020

    Addex Provides Trading Update and Completes 2019 with Cash Position of CHF31.5 million

  • 01.08
    2020

    Addex to Attend 38th Annual J.P. Morgan Healthcare Conference

  • 12.20
    2019

    Addex to Receive Additional $800K Funding from Indivior for GABAB PAM Addiction Program

  • 12.18
    2019

    ADDEX THERAPEUTICS PUBLICLY FILES REGISTRATION STATEMENT WITH THE U.S. SEC TO FACILITATE NASDAQ LISTING OF ADSs REPRESENTING SHARES

  • 12.03
    2019

    Addex: Van Leeuwenhoeck Issues Update Equity Research Report

    Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • Next

Contact us

If you have any questions please let me know
  • Contact form
2026 © Addex therapeutics